Alto Neuroscience, Inc. (ANRO) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$29.13M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$27.14M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$14.95M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA -$18.58M; Operating income (m); Depreciation and amortization (m).
Complete source-backed ebitda history.
- Available history
- 2023-03-31 to 2025-06-30
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | (m) | -$29.13M | (m) | (m) | (m) | $0.00* | -$19.76M* | (m) | $22.11M | (m) | (m) |
|---|
| 2026-03-31 | Reported | (m) | -$27.14M | (m) | (m) | (m) | $556.00K | -$27.09M | (m) | $20.29M | (m) | (m) |
|---|
| 2025-09-30 | Reported | (m) | -$14.95M | (m) | (m) | (m) | $0.00* | -$9.92M* | (m) | $10.53M | (m) | $0.00* |
|---|
| 2025-06-30 | Reported | -$18.58M | (m) | (m) | (m) | (m) | $0.00* | -$13.78M* | (m) | $13.12M | (m) | $0.00* |
|---|
| 2025-03-31 | Reported | -$15.51M | (m) | (m) | (m) | (m) | $24.00K | -$16.56M | (m) | $9.97M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$16.83M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$18.69M | (m) | (m) | (m) | (m) | $1.00M* | -$11.73M* | (m) | $13.06M | (m) | $0.00* |
|---|
| 2024-06-30 | Reported | -$18.24M | (m) | (m) | (m) | (m) | $340.00K* | -$11.69M* | (m) | $13.18M | (m) | $0.00* |
|---|
| 2024-03-31 | Reported | -$14.29M | (m) | (m) | (m) | (m) | $224.00K | -$10.98M | (m) | $9.95M | (m) | $0.00 |
|---|
| 2023-12-31 | Reported | -$11.65M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$9.62M | (m) | (m) | (m) | (m) | $43.00K* | -$7.76M* | (m) | $7.97M | (m) | (m) |
|---|
| 2023-06-30 | Reported | -$9.03M | (m) | (m) | (m) | (m) | $54.00K* | -$6.63M* | (m) | $7.07M | (m) | (m) |
|---|
| 2023-03-31 | Reported | -$7.12M | (m) | (m) | (m) | (m) | $21.00K | -$7.52M | (m) | $5.61M | (m) | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | (m) | -$66.36M | (m) | (m) | (m) | $24.00K | -$51.77M | (m) | $45.62M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$68.11M | (m) | (m) | (m) | (m) | $2.08M | -$47.42M | (m) | $47.00M | (m) | $0.00 |
|---|
| 2023-12-31 | Reported | -$37.44M | (m) | (m) | (m) | (m) | $470.00K | -$33.45M | (m) | $30.29M | (m) | $0.00 |
|---|